Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART0380 in advanced or metastatic solid tumors as monotherapy and in combination
2024-511534-12-00Phase 2Authorised
- Sponsor
- Artios Pharma
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of alnodesertib in Nonhematologic neoplasms, ovarian cancer, primary peritoneal cancer (PPC) and 5 more (9 arms), sponsored by Artios Pharma. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 2 more. Planned start Mar 2023; status: authorised.
02
Drugs
alnodesertib
03
Conditions
Nonhematologic neoplasmsovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-511534-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511534-12-00.